[{"from": "human", "value": "Describe this molecule. [C][N][N][=C][Branch1][Branch1][N][=N][Ring1][Branch1][C][=N][C][=C][Branch1][Branch1][C][=C][Ring1][=Branch1][C][=C][Branch2][Ring1][=N][C][=C][Branch1][Branch1][C][=C][Ring1][=Branch1][N][C][C@@H1][Branch1][=Branch1][O][C][Ring1][Branch1][=O][C][O][P][=Branch1][C][=O][Branch1][C][O][O][F]"}, {"from": "gpt", "value": "The molecule is a member of the oxazolidinone class of antibiotics, which includes the previously approved [linezolid] and is generally effective against multidrug-resistant Gram-positive bacteria. Tedizolid is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and is generally more effective and more tolerable than [linezolid].  Tedizolid was approved by the FDA on June 20, 2014, for sale by Cubist Pharmaceuticals as tedizolid phosphate (SIVEXTRO\u00ae). This product is currently available as both an oral tablet and as a powder for intravenous injection."}]